Davenport & CO LLC Nektar Therapeutics Transaction History

Davenport & CO LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 18, 2022	SELL	$3.17 - $6.17 $149,941 - $291,841	-47,300 Closed	0 $0
Q1 2022 May 02, 2022	SELL	$4.16 - $13.72 $6,240 - $20,580	-1,500 Reduced 3.07%	47,300 $255,000
Q4 2021 Feb 10, 2022	SELL	$10.83 - $18.41 $222,242 - $377,791	-20,521 Reduced 29.6%	48,800 $659,000
Q3 2021 Oct 14, 2021	BUY	$13.07 - $18.84 $130,700 - $188,400	10,000 Added 16.86%	69,321 $1.24 Million
Q2 2021 Jul 28, 2021	SELL	$16.52 - $20.4 $82,253 - $101,571	-4,979 Reduced 7.74%	59,321 $1.01 Million

Q1 2021 Apr 28, 2021	BUY	$16.56 - $25.46 $74,520 - $114,570	4,500 Added 7.53%	64,300 $1.29 Million
Q4 2020 Jan 13, 2021	BUY	$15.77 - $19.03 $23,655 - $28,545	1,500 Added 2.57%	59,800 $1.02 Million
Q3 2020 Oct 15, 2020	SELL	$16.59 - $24.79 $70,507 - $105,357	-4,250 Reduced 6.79%	58,300 $967,000
Q1 2020 May 05, 2020	BUY	$14.47 - $27.96 $94,055 - $181,740	6,500 Added 11.6%	62,550 $1.12 Million
Q4 2019 Jan 22, 2020	BUY	$15.87 - $23.12 $753,428 - $1.1 Million	47,475 Added 553.64%	56,050 $1.21 Million
Q2 2019 Jul 10, 2019	BUY	$31.0 - $36.3 $3,100 - $3,629	100 Added 1.18%	8,575 $305,000
Q1 2019 Apr 17, 2019	BUY	$31.58 - $46.35 $267,640 - $392,816	8,475 New	8,475 $285,000

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Davenport & CO LLC, based on Form 13F filings with the SEC.

Stay updated on Davenport & CO LLC with notifications on news.